Texolite Joint Compound by United States Gypsum

Product Description

Texolite Joint Compound was a construction finishing product manufactured by United States Gypsum (USG), one of the largest gypsum and building materials companies in the United States. Joint compounds of this type were widely used throughout the construction industry during the mid-twentieth century as a finishing material applied to drywall seams, nail dimples, and surface imperfections before painting or texturing. The Texolite line represented part of USG’s broader portfolio of interior finishing products marketed to contractors, builders, and tradespeople working on both residential and commercial construction projects.

United States Gypsum had an extensive distribution network that placed products like Texolite Joint Compound on job sites across the country, from housing developments and office buildings to schools, hospitals, and industrial facilities. The product was designed for ease of application and smooth finishing, making it a staple material in the toolkit of drywall finishers, plasterers, and general construction workers throughout the decades of its production and use.

Beyond its primary use as a joint compound, products in the Texolite line have also been associated in litigation records with ceiling tile applications and pipe insulation contexts, reflecting the broad range of construction materials that USG manufactured and sold under related brand names during the same era. This overlap in product lines and branding has been a significant factor in the litigation history surrounding Texolite and related USG products.

Asbestos Content

Litigation records document that Texolite Joint Compound contained asbestos as a component of its formulation. Asbestos was commonly added to joint compounds and related finishing products during much of the twentieth century because of its functional properties: the mineral fibers improved the workability of the compound, reduced cracking during drying and curing, and enhanced the durability and adhesion of the finished surface.

Chrysotile asbestos was the most commonly used variety in building and finishing products of this type, though litigation records in cases involving USG products have addressed the presence of asbestos without always specifying fiber type in publicly available documentation. Plaintiffs alleged that USG was aware, or should have been aware, of the hazards associated with asbestos-containing joint compounds during the period when these products were manufactured and sold, yet continued to produce and market them without adequate warnings to the workers who would be handling them regularly and in substantial quantities.

The use of asbestos in joint compounds was widespread across the industry, and regulatory pressure—including eventual AHERA-era guidelines and OSHA standards addressing asbestos in construction—contributed to the reformulation or discontinuation of asbestos-containing versions of these products. However, materials produced and installed before those reformulations remained in place in buildings for decades, continuing to pose exposure risks during renovation, repair, and demolition work long after asbestos-free alternatives became standard.

How Workers Were Exposed

Workers exposed to Texolite Joint Compound faced significant inhalation risks during several stages of the product’s use. The primary exposure pathway documented in litigation records involved the mixing, application, sanding, and cleanup of joint compound containing asbestos fibers. Each of these tasks had the potential to release respirable asbestos fibers into the work environment.

Dry mixing of powdered joint compound was among the most hazardous tasks, as pouring and agitating the dry material could generate dense airborne dust. Sanding of dried compound between coats—a routine and necessary step in achieving a smooth finish—was similarly identified in litigation records as a high-exposure activity, releasing fine asbestos-laden particles that could remain suspended in indoor air for extended periods.

Industrial workers generally, as well as drywall finishers, plasterers, construction laborers, and building tradespeople working in proximity to finishing operations, were documented as having been exposed to the product. In industrial settings, where construction and renovation work was ongoing in facilities such as factories, power plants, and manufacturing plants, workers who were not directly applying the compound could nonetheless inhale fibers released by finishing work occurring nearby. This bystander exposure has been addressed in multiple litigation contexts involving USG joint compound products.

Plaintiffs alleged that the enclosed or poorly ventilated conditions common in many construction and industrial work environments compounded the exposure risk, as fibers had limited opportunity to dissipate. Workers were frequently not provided with appropriate respiratory protection, and plaintiffs alleged that warnings on product packaging were either absent or inadequate to convey the severity of the health risks associated with repeated asbestos inhalation.

Long-term or repeated exposure to airborne asbestos fibers is associated with serious and often fatal diseases, including mesothelioma, asbestosis, and asbestos-related lung cancer. The latency period for these diseases—often spanning twenty to fifty years between initial exposure and diagnosis—means that individuals exposed to Texolite Joint Compound and similar products decades ago may only now be receiving diagnoses linked to that occupational exposure.

Texolite Joint Compound is classified as a Tier 2 product for purposes of legal reference, meaning that claims related to this product proceed through the civil litigation system rather than through an established asbestos bankruptcy trust fund. United States Gypsum has been a defendant in asbestos litigation, and litigation records document that plaintiffs have brought claims alleging injury from exposure to USG joint compound products including those marketed under the Texolite name.

Individuals who were exposed to Texolite Joint Compound and have received a diagnosis of mesothelioma, asbestosis, lung cancer, or another asbestos-related disease may have the right to pursue compensation through personal injury litigation. The families of workers who have died from asbestos-related diseases may have grounds to bring wrongful death claims.

Because claims involving Tier 2 products are litigated rather than resolved through trust fund submissions, outcomes vary based on the specific facts of each case, including the nature and duration of exposure, the plaintiff’s diagnosis, and the evidentiary record connecting the plaintiff’s illness to the specific product and manufacturer. Litigation records document that plaintiffs in asbestos cases involving joint compound products have alleged failure to warn, negligence, and product liability as the primary legal theories.

Individuals seeking to evaluate their legal options should consult with an attorney experienced in asbestos litigation. Statute of limitations periods vary by state and typically begin running from the date of diagnosis rather than the date of exposure, but early consultation is advisable to preserve evidence and witness testimony. Documentation of work history, employer records, co-worker testimony, and medical records all play important roles in establishing a viable claim involving Texolite Joint Compound or related USG products.